Delcath Systems (NASDAQ:DCTH) Issues Earnings Results

Delcath Systems (NASDAQ:DCTH) announced its earnings results on Monday. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26, FiscalAI reports. The firm had revenue of $35.10 million during the quarter, compared to analysts’ expectations of $25.99 million. Delcath Systems had a return on equity of 5.78% and a net margin of 6.05%.

Here are the key takeaways from Delcath Systems’ conference call:

• Record results and higher outlook: Third-quarter revenue rose 71% year over year to $35.1 million, with net income of $7 million and adjusted EBITDA of $11.5 million. Delcath raised 2026 revenue guidance to $115 million–$117 million and expects positive adjusted EBITDA for the year.
• Commercial adoption is expanding: HEPZATO treatment volume increased 72% year over year, with about 0.6 new patient starts per site per month and 33 active U.S. centers. The company expects at least 36 centers by year-end and cited growing use alongside systemic therapies as a demand driver.
• Pipeline progress is mixed: Delcath expects an interim analysis of its colorectal trial around the middle of 2027 and plans an early-2027 IND submission for cholangiocarcinoma, while breast-cancer trial enrollment remains slower than anticipated and its interim-analysis timing is unclear.
• Investment and seasonality remain considerations: R&D spending rose with increased trial activity, while commercial investment continued; management said quarterly profitability may vary. Fourth-quarter guidance assumes fewer treatment days around the holidays and a seasonal slowdown in new patient starts.

Delcath Systems Stock Performance

Shares of DCTH opened at $20.10 on Wednesday. The firm has a market cap of $697.47 million, a P/E ratio of 125.62 and a beta of 0.62. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $21.84. The firm’s 50 day moving average price is $15.60 and its two-hundred day moving average price is $12.54.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Weiss Ratings lowered Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. BTIG Research upped their price target on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright increased their price objective on Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Zacks Research cut Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.33.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analysts’ consensus estimate of a $0.09 loss, and revenue of $35.1 million, well above the $26.0 million expected. The company also raised its 2026 revenue outlook to $115 million–$117 million, compared with consensus of $106.2 million. Earnings report
• Positive Sentiment: HC Wainwright reiterated its Buy rating and lifted its price target from $32 to $36. It also raised its EPS forecasts for 2028, 2029 and 2030 to $0.68, $1.08 and $1.61, respectively. The stock recently reached a new 12-month high following the earnings news. Delcath reaches a 12-month high
• Negative Sentiment: HC Wainwright lowered its Q2 2027 EPS estimate slightly, to $0.11 from $0.12. This modest near-term reduction contrasts with its higher longer-term forecasts. HC Wainwright research

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.